Important clinical research progress in lung cancer in 2022
Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated. In terms of...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Editorial Office of China Oncology
2023-03-01
|
| Series: | Zhongguo aizheng zazhi |
| Assuntos: | |
| Acceso en liña: | http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2023.03.004 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|